净现值1
癌症研究
医学
内科学
肿瘤科
生物
遗传学
核型
基因
染色体
作者
Ghayas C. Issa,Ibrahim Aldoss,John F. DiPersio,Branko Cuglievan,Richard M. Stone,Martha Arellano,Michael J. Thirman,Manish R. Patel,David S. Dickens,Shalini Shenoy,Neerav Shukla,Hagop M. Kantarjian,Scott A. Armstrong,Florian Perner,Jennifer A. Perry,Galit Rosen,Rebecca G. Bagley,Michael L. Meyers,Peter Ordentlich,Yu Gu
出处
期刊:Nature
[Nature Portfolio]
日期:2023-03-15
卷期号:615 (7954): 920-924
被引量:467
标识
DOI:10.1038/s41586-023-05812-3
摘要
Abstract Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function 1–3 . The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene ( NPM1 ) 4–6 . KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia 7,8 . Here, we describe the results of the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI